Posted inGastroenterology Internal Medicine news
Moving Beyond Injectables: SOR102 Shows Promise as an Oral Dual-Inhibitor for Ulcerative Colitis
A Phase 1 trial of SOR102, a first-in-class oral bispecific antibody targeting TNF and IL-23, demonstrates favorable safety and preliminary clinical activity in patients with ulcerative colitis, suggesting a potential shift toward localized, dual-targeted oral biologics.